# A new method for the synthesis of [1,4] diazepino [6,5-b] indole derivatives

S. Yu. Ryabova, L. M. Alekseeva, N. A. Rastorgueva, E. A. Lisitsa, D. M. Papakhin, V. A. Parshin, and V. G. Granik\*

State Scientific Center for Antibiotics, 3a ul. Nagatinskaya, 117003 Moscow, Russian Federation. E-mail: vggranik@mail.ru

Reactions of 3-[(*N*-aryl-*N*-chloroacetyl)amino]-2-formylindoles with substituted anilines gave 1,4-diaryl-2-oxo-1,2,3,6-tetrahydro[1,4]diazepino[6,5-*b*]indol-4-ium chlorides and those with 4-aminopyridine yielded 4-amino-1-(1-aryl-2-oxo-2,5-dihydro-1*H*-pyrido[3,2-*b*]indol-3-yl)pyridinium chlorides. Reduction of 1,2,3,6-tetrahydrodiazepinoindol-4-ium chlorides afforded the corresponding hexahydro derivatives. An alternative synthesis of 1-(4-nitrophenyl)-3-oxo-4-phenyl-1,2,3,4,5,6-hexahydro[1,4]diazepino[6,5-*b*]indole from 3-[*N*-(4-nitrophenyl)amino]-2-[(phenylimino)methyl]indole was developed. The method involves the following sequence of transformations: reduction, chloroacetylation, and intramolecular alkylation.

**Key words:** 3-[(*N*-aryl-*N*-chloroacetyl)amino]-2-formylindoles, arylamines, 4-aminopyridine, [1,4]diazepino[6,5-*b*]indoles, pyrido[3,2-*b*]indoles, 2-formyl-3-[*N*-(4-nitrophenyl)amino]indole, condensation, reduction, chloroacetylation, alkylation, Triton B.

A great number of polycyclic compounds containing the indole fragment are highly efficient drugs<sup>1</sup> (*e.g.*, carbidine, pyrazidol, tetrindol, incazan, dimebon, diazolin, *etc*).

Along with the indole derivatives listed above, benzo[1,4]diazepine drugs (in particular, chlozepid, phenazepam, and diazepam) are widely used in clinical practice. That is why a combination of the indole and diazepine fragments in one molecule is of undoubted interest for a search for novel drugs. Some [1,4]diazepino[1,2-a]indole derivatives have already been found to exhibit pronounced psychotropic activity. However, [1,4]diazepino[6,5-b]indoles remain poorly studied, probably because they are not easily accessible.

Recently,  $^{6,7}$  we have developed a method for the synthesis of [1,4]diazepino[6,5-b]indole N-oxides by reactions of 3-[(N-aryl-N-chloroacetyl)amino]-2-formylindoles (1a—c) with hydroxylamine.

The goal of the present work was to obtain new [1,4]diazepino[6,5-b]indoles containing no nitrone fragment and study their biological activity. First, we carried out reactions of earlier<sup>7</sup> described 2-formylindoles **1a**—**c** with substituted aromatic amines (Scheme 1) with the aim of obtaining azomethines **2**, which subsequently could be subjected to intramolecular alkylation under more drastic conditions to give quaternary salts of the diazepinoindole series. We took into account that imines with *N*-aryl substituents undergo *N*-alkylation only with great difficulty. However, it turned out that in reactions of alde-

hydes 1a-c with arylamines under mild conditions, azomethines 2 undergo in situ cyclization into the corresponding 1,4-diaryl-2-oxo-1,2,3,6-tetrahydro[1,4]diazepino[6,5-b]indol-4-ium chlorides (3a-e) in high yields.

Such an easy intramolecular alkylation is probably duavoide to direct polar transition-state conjugation of the lone electron pair of the N(1) atom with the  $C=N^+$  group in positions 4 and 5 of the tricycles, which stabilizes the final products, namely, quaternary salts of diazepino-indoles.

The structures of salts  $3\mathbf{a} - \mathbf{e}$  were proven by <sup>1</sup>H NMR spectra, which show, apart from signals for aromatic protons, signals for the NH and CH<sub>2</sub> protons (Table 1). The upfield shift of the signals for the H(10) protons ( $\delta$  6.3—6.5) is due to the anisotropic effect of the benzene ring of the 1-aryl substituent, which is not coplanar with the tricyclic system.

Reduction of chlorides  $3\mathbf{a} - \mathbf{e}$  with NaBH<sub>4</sub> occurred easily to give the corresponding hexahydro derivatives  $4\mathbf{a} - \mathbf{e}$  (see Scheme 1) in high yields. In the <sup>1</sup>H NMR spectra of compounds  $4\mathbf{a} - \mathbf{e}$ , all signals for the protons are shifted upfield compared to those in the spectra of chlorides  $3\mathbf{a} - \mathbf{e}$ , the singlet for the H(5) proton at  $\delta$  9.6 disappears, but a signal for H<sub>2</sub>C(5) (2 H) appears at  $\delta$  4.10–4.28.

Apart from the aforementioned aromatic amines, we also used 4-aminopyridine in reactions with 3-[(N-aryl-N-chloroacetyl)] amino]-2-formylindoles 1a-c. We chose

#### Scheme 1

**1:**  $R = NO_2(a), H(b), OEt(c)$ 

**3,4 a b c d e** R NO<sub>2</sub> NO<sub>2</sub> NO<sub>2</sub> H OEt R' H OMe CI OMe OMe

Reagents and conditions: i. ArNH<sub>2</sub>, PriOH, 70 °C; ii. NaBH<sub>4</sub>, MeOH, 20 °C, 1 h.

this heterocyclic amine because the resulting diazepinium salts **3f—h** containing the 4-aminopyridine fragment (Scheme 2) could exhibit anticholinesterase properties. It should be noted that the 4-aminopyridine fragment is a part of the anticholinesterase (memory-improving) drugs

tacrine and amiridin. It is also known that 4-amino-pyridine itself (fampridine) favors a release of acetylcholine from presynaptic terminals of motor nerves.

However, it turned out that the condensation does not lead to Schiff bases 2 with subsequent cyclization into

## Scheme 2

**1, 6:**  $R = NO_2(a)$ , H(b), OEt(c)

Reagents and conditions: i. 4-aminopyridine, PriOH, reflux, 2—4.5 h.

Table 1. <sup>1</sup>H NMR spectra (DMSO-d<sub>6</sub>) of [1,4]diazepino[6,5-b]indoles 3a-e, 4a-e, and 13

Com-		δ ( <i>J</i> /Hz)												
po- und	H <sub>2</sub> C(3) (s, 2 H)	H <sub>2</sub> C(5) (s, 2 H)	H(5) (s, 1 H)	H(7) (d*, 1 H)	H(8) (t*, 1 H)	H(9) (t*, 1 H)	H(10) (d*, 1 H)	N(6)H (br.s, 1 H)	4-RC <sub>6</sub> H <sub>4</sub>	4-R´C <sub>6</sub> H <sub>4</sub>				
3a	5.22	_	9.85	_	7.48	6.95	6.39	13.07	7.74, 8.42 (A <sub>2</sub> B <sub>2</sub> system,	7.65 (m, 4 H, H(7), H(3´)—H(5´));				
3b**	5.18	-	9.68	7.66	7.48	6.96	6.39	12.76	4 H, C <sub>6</sub> H <sub>4</sub> NO <sub>2</sub> ) 7.71, 8.39 (A <sub>2</sub> B <sub>2</sub> system,	7.94 (m, 2 H, H(2'), H(6')) 7.22, 7.88 (A <sub>2</sub> B <sub>2</sub> system, 4 H, C <sub>6</sub> H <sub>4</sub> OMe); 3.89 (s, 3 H, OMe)				
3c	5.19	_	9.85	7.67	7.49	6.96	6.33	12.88	4 H, C <sub>6</sub> H <sub>4</sub> NO <sub>2</sub> ) 7.80, 8.42 (A <sub>2</sub> B <sub>2</sub> system,	7.71, 7.92 (A <sub>2</sub> B <sub>2</sub> system, 4 H, C <sub>6</sub> H <sub>4</sub> Cl)				
3d	5.15	_	9.66	_	7.60	6.88	6.23	12.85	4 H, C <sub>6</sub> H <sub>4</sub> NO <sub>2</sub> ) 7.40-7.56 (m, 6 H,	7.22, 7.91 (A <sub>2</sub> B <sub>2</sub> system, 4 H, C <sub>6</sub> H <sub>4</sub> OMe);				
3e	5.12	_	9.62	7.61	7.45	6.92	6.39	12.84	Ph, H(7)) 7.06, 7.33 ( $A_2B_2$ system, 4 H, $C_6\underline{H}_4$ OEt); 1.36 (t, 3 H, OCH <sub>2</sub> C $\underline{H}_3$ , J = 7.0); 4.10 (q, 2 H,	3.88 (s, 3 H, OMe) 7.21, 7.88 (A <sub>2</sub> B <sub>2</sub> system, 4 H, C <sub>6</sub> H <sub>4</sub> OMe); 3.88 (s, 3 H, OMe)				
4a	4.89	4.28	_	7.40	6.80	6.76	6.35	11.55	OC $\underline{\text{H}}_2$ CH <sub>3</sub> , $J = 7.0$ ) 7.61, 8.23 (A <sub>2</sub> B <sub>2</sub> system,	7.25 (t, H(3'), H(5'), J = 8.4); 7.08 (t, H(4'));				
4b**	4.81	4.18	_	7.40	7.08	6.80	6.37	11.50	4 H, C <sub>6</sub> H <sub>4</sub> NO <sub>2</sub> ) 7.60, 8.21 (A <sub>2</sub> B <sub>2</sub> system,	6.99 (d, 2 H, H(2'), H(6')) 6.85, 6.96 (A <sub>2</sub> B <sub>2</sub> system, 4 H, C <sub>6</sub> H <sub>4</sub> OMe);				
4c**	4.88	4.27	_	7.41	7.08	6.80	6.38	11.49	4 H, C <sub>6</sub> H <sub>4</sub> NO <sub>2</sub> ) 7.61, 8.22 (A <sub>2</sub> B <sub>2</sub> system,	3.69 (s, 3 H, OMe) 6.99, 7.27 (A <sub>2</sub> B <sub>2</sub> system, 4 H, C <sub>6</sub> <u>H</u> <sub>4</sub> Cl)				
4d	4.78	4.13	_	-	7.02	6.71	6.30	11.37	4 H, C <sub>6</sub> H <sub>4</sub> NO <sub>2</sub> ) 7.18–7.45 (m, 6 H,	6.85, 6.94 (A <sub>2</sub> B <sub>2</sub> system, 4 H, C <sub>6</sub> H <sub>4</sub> OMe);				
4e**	4.75	4.10	_	7.31	7.00	6.71	6.40	11.19	Ph, H(7)) 6.82, $6.94(A_2B_2 \text{ system},4 \text{ H, } C_6\underline{H}_4\text{OEt});1.37 \text{ (t, 3 H, OCH}_2\text{C}\underline{H}_3,J = 7.0)$ ; $4.02  (q, 2 H, CM)$	3.67 (s, 3 H, OMe) 6.86, 7.20 (A <sub>2</sub> B <sub>2</sub> system, 4 H, C <sub>6</sub> <u>H</u> <sub>4</sub> OMe); 3.70 (s, 3 H, OMe)				
13***	4.96 (H <sub>2</sub> C(2))	5.50	_	7.95	7.18-	-7.37	6.91	_	OC $\underline{H}_2$ CH $_3$ , $J = 7.0$ ) 7.02, 8.16 (A $_2$ B $_2$ system, 4 H, C $_6$ H $_4$ NO $_2$ )	7.18—7.37 (Ph)				

<sup>\*</sup> J = 8.2 - 8.4 Hz.

compounds **3f—h**. Instead, the condensation involves the pyridine N atom and the Cl atom of the chloroacetyl fragment of compounds **1a—c**. Apparently, the first-step products are pyridinium salts **5** with a substantially higher CH acidity of the CH<sub>2</sub> group. This favors intramolecular cyclization *via* the 2-formyl group, giving compounds of the  $\delta$ -carboline structure: 4-amino-1-(1-aryl-2-oxo-2,5-dihydro-1*H*-pyrido[3,2-*b*]indol-3-yl)pyridinium chlo-

rides (6a—c). In contrast to the  $^1H$  NMR spectra of diazepinoindoles 3a—e, the spectra of compounds 6a—c show no signals for the  $CH_2$  group but contain broadened signals (2 H) at  $\delta$  8.6—8.7 due to the  $NH_2$  groups in the 4-aminopyridinium substituent.

Earlier,  $^{6,11}$  this type of cyclization leading to  $\delta$ -carboline derivatives has been observed by us in reactions of aldehydes 1a-c with pyridine or sodium nitrite.

<sup>\*\*</sup> The spectrum was recorded in DMSO-CCl<sub>4</sub>.

<sup>\*\*\*</sup> The spectrum also contains a signal at  $\delta$  2.79 (s, 3 H, COMe).

It was interesting to approve an alternative synthesis of [1,4] diazepino [6,5-b] indoles with compound  $\mathbf{3a}$  as an example. For this purpose, we synthesized 3-[(4-nitrophenyl) amino]-2-[(phenyl) imino)methyl] indole (7) from aniline and 2-formyl-3-[N-(4-nitrophenyl) amino] indole (8), as well as from aniline and 2-dimethyliminiomethyl-3-[N-(4-nitrophenyl) amino] indole chloride (9) (an intermediate in the Vilsmeier synthesis of 2-formylindole 8) (Scheme 3). We expected that chloroacetylation of phenyliminomethylindole 7 yields, through the formation of azomethine 2, the target diazepinoindole  $\mathbf{3a}$ .

#### Scheme 3

**Reagents and conditions:** *i.* Pr<sup>i</sup>OH, reflux, 13.5 h; *ii.* Pr<sup>i</sup>OH, reflux, 0.5 h.

However, the chloroacetylation of compound 7 in boiling toluene in the presence of anhydrous Na<sub>2</sub>CO<sub>3</sub> or in

DMF with triethylamine at 20 °C gave a complex mixture of products, from which we failed to isolate individual compounds. TLC analysis showed unambiguously that diazepinoindole **3a** does not form under these conditions (see Scheme 3).

Starting from phenyliminomethylindole 7, we developed a method for the synthesis of other [1,4]diazepino[6,5-b]indole derivatives. Compound 7 was reduced with NaBH<sub>4</sub> to phenylaminomethylindole 10, which was treated with chloroacetyl chloride to give the corresponding N-chloroacetyl derivative 11. Intramolecular alkylation of compound 11 on heating in methanol with Triton B (benzyltrimethylammonium hydroxide) yielded a compound whose mass spectrum (ESI) contains peaks with m/z 399 [M + H]<sup>+</sup>, 421 [M + Na]<sup>+</sup>, and 437 [M + K]<sup>+</sup> characteristic of 3-oxodiazepinoindole 12. However, we failed to purify compound 12 for analysis by recrystallization or column chromatography. It was characterized in the form of 6-acetyl derivative 13 (Scheme 4).

Biological tests with mice revealed the low toxicity of injected compounds  $\bf 3a-e$  and  $\bf 4a-e$  ( $\rm LD_{50}>1000~mg~kg^{-1}$ ). Compounds  $\bf 4a-e$  have no effect on the central nervous system and experimentally induced inflammation in animals. All diazepinoindole chlorides  $\bf 3a-e$  used in doses from 1/10 to 1/20 of  $\rm LD_{50}$  exhibit antihypoxic activity with models of hypoxic and hypobaric hypoxia at the piracetam level.

Using a standard avoidance task procedure,  $^{12}$  we studied the effect of the aminopyridinium salts of  $\delta$ -carbolines (6a-c) on the cognitive functions (learning and memory) of non-breeded male mice (18-22 g in weight). Deficit in learning was induced by scopolamine (1 mg kg $^{-1}$ ) injected intraperitoneally as an m-choline blocking agent 15 min before learning tests. The tested low-toxicity compounds ( $LD_{50} > 1000$  mg kg $^{-1}$  (p.os)) were administered

## Scheme 4

Reagents and conditions: *i*. NaBH<sub>4</sub>, MeOH, 20 °C, 2.5 h; *ii*. ClCH<sub>2</sub>COCl, C<sub>6</sub>H<sub>6</sub>, 25 °C, 1 h 40 min; *iii*. Triton B, Me<sub>2</sub>CO, reflux, 1 h; *iv*. Ac<sub>2</sub>O, reflux, 1 h.

in doses of 6-25 and 100 mg kg<sup>-1</sup> p.os 40 min before learning tests. Compounds  $6\mathbf{a}-\mathbf{c}$  had a dose-dependent stimulating effect on the animal learning and memory. The positive effects of compounds  $6\mathbf{a}$ ,  $6\mathbf{b}$ , and  $6\mathbf{c}$  in a dose of 100 mg kg<sup>-1</sup> were observed in 63, 83, and 72% of the animals, respectively; for a dose of 25 mg kg<sup>-1</sup>, the respective percentages were 50, 40 and 60%. Because the medicinal properties of nootropic drugs are determined by their ability to boost the integrative brain activity, favor memory consolidation, and enhance cognitive functions, we compared these compounds with piracetam, the most familiar drug in this group, in efficiency. Chlorides  $6\mathbf{a}-\mathbf{c}$  proved to be more efficient than piracetam: its effect in a dose of 300 mg kg<sup>-1</sup> was 70%.

### **Experimental**

IR spectra were recorded on an FSM-1201 instrument (Nujol). Mass spectra were recorded on a Finnigan SSQ-710 mass spectrometer (EI, direct inlet probe). Mass spectra (ESI) were recorded on a Waters ZQ-2000 mass spectrometer; samples were injected without passing through a chromatography column. <sup>1</sup>H NMR spectra were recorded on Bruker AC-200 and Bruker AC-300 spectrometers in DMSO-d<sub>6</sub> according to the Bruker standard procedure. The course of the reactions was

monitored and the purity of the products was checked by TLC on Merck 60  $F_{254}$  plates. The yields, melting points, elemental analysis data, mass spectra, and IR spectra of the compounds obtained are summarized in Table 2. The <sup>1</sup>H NMR spectra of [1,4]diazepino[6,5-b]indoles 3a-e, 4a-e, and 13 are given in Table 1. Compounds 1a-e, <sup>7</sup>8, <sup>13</sup> and 9 <sup>7</sup> have been characterized earlier.

1,4-Diaryl-2-oxo-1,2,3,6-tetrahydro[1,4]diazepino[6,5-b]indol-4-ium chlorides (3a—e) (general procedure). An appropriate arylamine (1 mmol) was added to a suspension of 2-formylindole 1a—c (1 mmol) in PriOH (10 mL). The stirred reaction mixture was heated on a water bath to 70 °C; after 15—30 min, a precipitate formed. The suspension was cooled and chloride 3a—e was filtered off, washed with PriOH and Me<sub>2</sub>CO, and dried.

1,4-Diaryl-2-oxo-1,2,3,4,5,6-hexahydro[1,4]diazepino[6,5-b]indoles (4a—e) (general procedure). Sodium borohydride (5 mol) was added in portions at 20 °C to a suspension of chloride 3a—e (1 mol) in MeOH and the reaction mixture was stirred for 1 h. The precipitate of hexahydrodiazepinoindole 4a—e was filtered off, washed with MeOH, water, and again MeOH, and dried.

4-Amino-1-(1-aryl-2-oxo-2,5-dihydro-1*H*-pyrido[3,2-*b*]in-dol-3-yl)pyridinium chlorides (6a—c) (general procedure). 4-Aminopyridine (1 mmol) was added to a suspension of 2-formylindole 1a, 1b, or 1c (1 mmol) in Pr<sup>i</sup>OH (10 mL). The reaction mixture was refluxed with stirring for 2, 3.5, and 4.5 h,

Table 2. Yields, melting points, elemental analysis data, mass spectra, and IR spectra of the compounds obtained

Com- po- und		M.p./°C (solvent)	M	Found (%) Calculated			Molecular formula	MS, $m/z (I_{\rm rel} (\%))$	IR, $v_{\text{max}}/\text{cm}^{-1}$		
	(%)								NH	C=N <sup>+</sup>	СО
				С	Н	N			(NH <sub>2</sub> )		
3a	80	255—260 (MeOH)	432	63.73 63.80	4.26 3.95	12.88 12.94	$C_{23}H_{17}CIN_4O_3$	397 [M – HCl + H] <sup>+</sup> , 369 [M – HCl +H – CO] <sup>+</sup> , 419 [M – HCl + Na] <sup>+</sup>	3460	1693	1626
3b	92	265—268 (MeOH)	462	62.05 62.27	<u>4.43</u> 4.13	11.84 12.10	C <sub>24</sub> H <sub>19</sub> ClN <sub>4</sub> O <sub>4</sub>	427 [M – HCl + H] <sup>+</sup> , 400 [M – HCl + H – CO] <sup>+</sup> , 449 [M – HCl + Na] <sup>+</sup> , 465 [M – HCl + K] <sup>+</sup>	3444	1690	1625
3c	75	238—240 (MeOH)	466	59.10 59.11	3.49 3.45	11.83 11.98	$C_{23}H_{16}Cl_2N_4O_3$	431 [M – HCl + H] <sup>+</sup> , 403 [M – HCl + H – CO] <sup>+</sup>	-	_	_
3d	85	228—230 (Pr <sup>i</sup> OH)	417	67.76 67.55	5.13 4.95	9.84 9.74	$C_{24}H_{20}CIN_3O_2 \cdot \\ \cdot 0.5H_2O$	382 [M – HCl + H] <sup>+</sup> , 354 [M – HCl + H – CO] <sup>+</sup> , 763 [2 M – 2 HCl + H] <sup>+</sup>	3480	1687	1620
3e	90	230 (Pr <sup>i</sup> OH)	461	66.20 66.33	5.96 5.35	8.72 8.92	C <sub>26</sub> H <sub>24</sub> ClN <sub>3</sub> O <sub>3</sub> · ·0.5H <sub>2</sub> O*	426 [M – HCl + H] <sup>+</sup> , 398 [M – HCl + H] <sup>+</sup> , 857 [2 M – 2 HCl + H] <sup>+</sup>	_	_	_
<b>4a</b>	95	234—236 (EtOAc)	398	69.36 69.33	4.80 4.55	14.13 14.06	C <sub>23</sub> H <sub>18</sub> N <sub>4</sub> O <sub>3</sub>	$\begin{array}{l} 398 \ [M]^+ \ (24), \ 368 \\ [M-NO]^+ \ (12), \ 265 \\ [M-C_6H_5NCH_2CO]^+ \ (25), \\ 248 \ [M-NO_2C_6H_4-CO]^+ \\ (12), \ 232 \ [M-\\ -NO_2C_6H_4NCO-H_2]^+ \\ (100), \ 218 \ [C_6H_5NCH_2CO-\\ -HNO_2]^+ \ (48) \end{array}$	3355	_	1690

Table 2 (continued)

Com- po- und	Yield	M.p./°C (solvent)	M	Found (%) Calculated			Molecular	MS,	IR, $v_{\text{max}}/\text{cm}^{-1}$		
	(%)			Care	H		formula	$m/z (I_{\rm rel} (\%))$	NH (NH <sub>2</sub> )	C=N <sup>+</sup>	СО
4b	92	208—210 (EtOAc)	428	67.43 67.28	<u>5.09</u> 4.70	12.91 13.07	$\mathrm{C}_{24}\mathrm{H}_{20}\mathrm{N}_4\mathrm{O}_4$	428 [M] <sup>+</sup> (12), 398 [M – NO] <sup>+</sup> (2), 262 [M – NO <sub>2</sub> C <sub>6</sub> H <sub>5</sub> NCO – H <sub>2</sub> ] <sup>+</sup> (100)	_	_	_
4c	87	252—254 (decomp., MeOH— —EtOAc)	432	63.91 63.82	4.13 3.96	12.92 12.95	C <sub>23</sub> H <sub>17</sub> CIN <sub>4</sub> O <sub>3</sub>	432 [M] <sup>+</sup> (17), 402 [M – NO] <sup>+</sup> (5), 265 [M – – ClC <sub>6</sub> H <sub>4</sub> NCH <sub>2</sub> CO] <sup>+</sup> (100), 248 [M – NO <sub>2</sub> C <sub>6</sub> H <sub>4</sub> – CO] <sup>+</sup> (31), 234 [M – – NO <sub>2</sub> C <sub>6</sub> H <sub>4</sub> NCO] <sup>+</sup> (15), 218 [ClC <sub>6</sub> H <sub>4</sub> NCH <sub>2</sub> CO – HNO <sub>2</sub> ] <sup>+</sup> (78)	3335	_	1665
4d	93	208—209 (MeOH— —EtOAc)	383	74.97 75.17	<u>5.71</u> 5.52	10.97 10.96	$C_{24}H_{21}N_3O_2$	384 [M + H] <sup>+</sup> , 406 [M + + Na] <sup>+</sup> , 422 [M + K] <sup>+</sup> , 767 [2 M + H] <sup>+</sup> , 789 [2 M + + Na] <sup>+</sup> , 805 [2 M + K] <sup>+</sup>	3295	_	1665
4e	93	223—224 (MeOH— —EtOAc)	427	72.83 73.04	<u>6.17</u> 5.89	9.80 9.83	$C_{26}H_{25}N_3O_3$	428 [M + H] <sup>+</sup> , 450 [M + + Na] <sup>+</sup> , 466 [M + K] <sup>+</sup> , 855 [2 M + H] <sup>+</sup> , 877 [2 M + + Na] <sup>+</sup> , 893 [2 M + K] <sup>+</sup>	3120	_	1660
6a	58	>360 (EtOH— —H <sub>2</sub> O, 10: 1.25)	451	58.13 58.48	4.05 4.02	15.28 15.50	$C_{22}H_{16}CIN_5O_3$ · • $H_2O$	$398 [M - HCl + H]^+$	3400— —3100	1715	1625
6b	75	320 (decomp., EtOH— —H <sub>2</sub> O, 10:1.5)	415	63.15 63.54	4.84 4.85	13.27 13.47	C <sub>24</sub> H <sub>21</sub> CIN <sub>4</sub> O <sub>2</sub> ∙ •H <sub>2</sub> O	353 [M – HCl + H] <sup>+</sup>	3365— —3075	1645	1616
6c	72	330 (decomp., EtOH— —H <sub>2</sub> O, 10:1)	450	63.70 63.93	5.35 5.14	12.28 12.43	C <sub>22</sub> H <sub>16</sub> CIN <sub>5</sub> O <sub>3</sub> ···1.5H <sub>2</sub> O	397 [M – HCl + H] <sup>+</sup>	3390— —3090	1650	1620
7	80 (A), 75 (B)	114—116 (C <sub>6</sub> H <sub>6</sub> )	356	71.50 70.77	4.59 4.53	15.40 15.72	$C_{21}H_{16}N_4O_2$	379 [M + Na] <sup>+</sup> , 395 [M + K] <sup>+</sup> , 735 [2 M + + Na] <sup>+</sup> , 751 [2 M + K] <sup>+</sup> , 1107 [3 M + K] <sup>+</sup>	3302	_	_
10	70	186—188 (Pr <sup>i</sup> OH)	358	70.33 70.38	5.03 5.06	15.27 15.63	$C_{21}H_{18}N_4O_2$	380 [M + Na] <sup>+</sup> , 397 [M + K] <sup>+</sup> , 755 [2 M + K] <sup>+</sup>	3188, 3382	_	_
11	80	196—198 (EtOH)	434	63.30 63.52	4.63 4.40	12.90 12.88	$C_{23}H_{19}CIN_4O_5$	435 [M + H] <sup>+</sup> , 457 [M + + Na] <sup>+</sup> , 473 [M + K] <sup>+</sup> , 891 [2 M + Na], 907 [2 M + K] <sup>+</sup>	3296, 3329	_	1798
13	38	305—307 (DMF)	440	68.68 68.17	4.45 4.58	12.81 12.72	$C_{25}H_{20}N_4O_4$	441 [M + H] <sup>+</sup> , 463 [M + + Na] <sup>+</sup> , 2479 [M + K] <sup>+</sup> , 881 [2 M + H] <sup>+</sup> , 903 [2 M + Na] <sup>+</sup> , 919 [2 M + K] <sup>+</sup>	_	_	1697, 1664

<sup>\*</sup> Found (%): H<sub>2</sub>O, 1.57. Calculated (%): H<sub>2</sub>O, 1.91.

respectively (monitoring by TLC) and cooled. Chlorides 6a-c were filtered off, washed with  $Pr^iOH$  and  $Me_2CO$ , and dried.

**Chloride 6a.** <sup>1</sup>H NMR,  $\delta$ : 6.18 (d, 1 H,  $\tilde{H}(9)$ , J = 8.2 Hz); 6.86 (t, 1 H, H(8), J = 8.2 Hz); 7.32 (t, 1 H, H(7)); 7.58 (d,

1 H, H(6), J = 8.2 Hz); 7.00, 8.34 (A<sub>2</sub>B<sub>2</sub> system, 4 H, H(2′), H(6′), H(5′), H(5′)); 7.84, 8.53 (A<sub>2</sub>B<sub>2</sub> system, 4 H, C<sub>6</sub>H<sub>4</sub>NO<sub>2</sub>); 8.52 (s, 1 H, H(4)); 8.70 (br.s, 2 H, NH<sub>2</sub>); 12.3 (br.s, 1 H, N(5)H).

**Chloride 6b.** <sup>1</sup>H NMR,  $\delta$ : 6.00 (d, 1 H, H(9), J = 8.2 Hz); 6.83 (t, 1 H, H(8), J = 8.2 Hz); 7.32 (t, 1 H, H(7)); 7.00, 8.34 (A<sub>2</sub>B<sub>2</sub> system, 4 H, H(2′), H(6′), H(3′), H(5′)); 7.50, 7.75 (both m, 3 H each, H(6) and H(2′), H(6′), H(3′)—H(5′)); 8.50 (s, 1 H, H(4)); 8.60 (br.s, 2 H, NH<sub>2</sub>); 12.1 (br.s, 1 H, N(5)H).

Chloride 6c. <sup>1</sup>H NMR,  $\delta$ : 1.40 (t, 3 H, OCH<sub>2</sub>CH<sub>3</sub>, J = 7.0 Hz); 4.15 (q, 2 H, OCH<sub>2</sub>Me, J = 7.0 Hz); 6.18 (d, 1 H, H(9), J = 8.2 Hz); 6.86 (t, 1 H, H(8), J = 8.2 Hz); 7.32 (t, 1 H, H(7), J = 8.2 Hz); 7.58 (d, 1 H, H(6), J = 8.2 Hz), 7.00, 8.34 (A<sub>2</sub>B<sub>2</sub> system, 4 H, H(2′), H(6′), H(3′), H(5′)); 7.20, 7.50 (A<sub>2</sub>B<sub>2</sub> system, 4 H, C<sub>6</sub>H<sub>4</sub>Et); 8.52 (s, 1 H, H(4)); 8.60 (br.s, 2 H, NH<sub>2</sub>); 12.1 (br.s, 1 H, N(5)H).

**3-[N-(4-Nitrophenyl)amino]-2-[(phenylimino)methyl]indole (7).** *A.* Aniline (3.24 mL, 35.6 mmol) was added to a suspension of aldehyde **8** (5 g, 17.8 mmol) in Pr<sup>i</sup>OH (500 mL). The reaction mixture was refluxed with stirring for 13.5 h and evaporated to dryness. The residue was refluxed with benzene (100 mL) for 5 min. The resulting solution was cooled and the precipitate was filtered off, washed with benzene and MeOH, and dried. The yield of compound **7** was 5.07 g.  $^{1}$ H NMR,  $\delta$ : 6.81, 8.06 (m, 4 H, C<sub>6</sub>H<sub>4</sub>NO<sub>2</sub>); 7.04, 7.33—7.17, 7.42, 7.49 (all m, 1 H, 5 H, 2 H, 1 H, H(4)—H(7), Ph); 8.57 (s, 1 H, H(1')); 9.33 (br.s, 1 H, N<u>H</u>PhNO<sub>2</sub>); 11.80 (br.s, 1 H, N(1)H).

**B.** Aniline (0.27 mL, 3 mmol) was added to a suspension of immonium salt **9** (0.7 g, 2 mmol) in Pr<sup>i</sup>OH (50 mL). The reaction mixture was refluxed with stirring for 30 min and evaporated to dryness. The residue was refluxed with benzene (20 mL) for 5 min. The resulting solution was cooled and the precipitate was filtered off, washed with benzene and MeOH, and dried. The yield of compound **7** was 0.54 g. A mixture of this compound with a sample from method **A** did not depress the melting point.

**3-(4-Nitrophenyl)amino-2-(phenylamino)methylindole (10).** Sodium borohydride (1.4 g, 38 mmol) was added in portions at 20 °C to a stirred solution of imine **7** (4.5 g, 12.6 mmol) in MeOH (100 mL). After 2.5 h, the precipitate was filtered off, washed with MeOH, and stirred for 30 min with water (150 mL) acidified with conc. HCl to pH 3. The resulting precipitate was filtered off, washed with water to pH 7 and MeOH, and dried. The yield of compound **10** was 3.22 g. <sup>1</sup>H NMR, δ: 4.27 (d, 2 H, CH<sub>2</sub>NHPh, J = 5.6 Hz); 5.96 (t, 1 H, CH<sub>2</sub>NHPh, J = 5.6 Hz); 6.44–6.77, 6.84–7.23, 7.37, 8.01 (all m, 5 H, 5 H, 1 H, 2 H, H(4)—H(7), C<sub>6</sub>H<sub>4</sub>NO<sub>2</sub>, Ph); 8.83 (s, 1 H, NHC<sub>6</sub>H<sub>4</sub>NO<sub>2</sub>); 11.17 (br.s, 1 H, N(1)H).

**2-**[*N*-(Chloroacetyl)-*N*-(phenyl)aminomethyl]-3-(4-nitrophenyl)aminoindole (11). Chloroacetyl chloride (0.09 mL, 1.1 mmol) and triethylamine (0.14 mL, 1 mmol) were added at 25 °C to a stirred suspension of indole **10** (0.36 g, 1 mmol) in dry benzene (5 mL). After 1 h 40 min, the precipitate was filtered off, washed with benzene, water, and MeOH, and dried. The yield of compound **11** was 0.35 g.  $^{1}$ H NMR,  $\delta$ : 4.01 (s, 2 H, C $\underline{H}_2$ N); 4.98 (s, 2 H, COC $\underline{H}_2$ Cl); 6.28, 6.83—7.35, 7.42, 7.83 (all m, 2 H, 8 H, 1 H, 2 H, H(4)—H(7),  $\underline{C}_6\underline{H}_4$ NO<sub>2</sub>, Ph); 8.51 (s, 1 H, N $\underline{H}$ PhNO<sub>2</sub>); 11.17 (br.s, 1 H, N(1)H).

**6-Acetyl-1-(4-nitrophenyl)-3-oxo-4-phenyl-1,2,3,4,5,6-hexahydro[1,4]diazepino[6,5-b]indole (13).** A 40% solution of Triton B (1.8 mL) in MeOH was added to a solution of chloroacetyl derivative **11** (0.8 g, 108 mmol) in anhydrous acetone (120 mL). The reaction mixture was refluxed for 1 h, cooled, and evaporated to dryness. The residue was triturated with MeOH—H<sub>2</sub>O (2 : 1). The resulting precipitate was filtered off, washed with water, and dried. The yield of crude 1-(4-nitrophenyl)-3-oxo-4-phenyl-1,2,3,4,5,6-hexahydro-6*H*-[1,4]diazepino[6,5-*b*]indole (**12**) was 0.68 g (93%). Compound **12** (0.43 g, 1 mmol) was refluxed as obtained in acetic anhydride (6 mL) for 1 h. On cooling, the resulting precipitate was filtered off, washed with acetic anhydride and MeOH, and dried. The yield of 6-acetyl[1,4]diazepino[6,5-*b*]indole **13** was 0.18 g.

#### References

- M. D. Mashkovskii, Lekarstvennye sredstva [Drugs], 14th ed., Novaya Volna, Khar´kov, 2000, 1, 540 pp.; 2, 608 pp. (in Russian).
- V. G. Granik, Lekarstva. Farmakologicheskii, biokhimicheskii i khimicheskii aspekty [Drugs. Pharmacological, Biochemical, and Chemical Aspects], Vuzovskaya Kniga, Moscow, 2001, p. 406 (in Russian).
- 3. US Pat. 3 736 324; Chem. Abstr., 1973, 79, 32118s.
- 4. F. Gatta, V. Zaccari, J. P. Huidolbro-Toro, and S. Chiavarelli, *Farmaco, Ed. Sci.*, 1975, **10**, 8.
- 5. US Pat. 3 689 503; Chem. Abstr., 1972, 77, 152241y.
- N. A. Lantsetti, S. Yu. Ryabova, L. M. Alekseeva, A. S. Shashkov, and V. G. Granik, *Izv. Akad. Nauk, Ser. Khim.*, 2002, 470 [Russ. Chem. Bull., Int. Ed., 2002, 51, 506].
- S. Yu. Ryabova, N. A. Rastorgueva, E. A. Lisitsa, L. M. Alekseeva, and V. G. Granik, *Izv. Akad. Nauk, Ser. Khim.*, 2003, 1312 [Russ. Chem. Bull., Int. Ed., 2003, 52, 1386].
- 8. J. Tennant, *Comprehensive Organic Chemistry*, Eds D. Barton and W. D. Ollis, Pergamon Press, Oxford—New York—Toronto—Sidney—Paris—Frankfurt, 1979.
- J. G. Cannon, *Pharmacology for Chemists*, Oxford University Press, New York—Oxford, 1999, 272 pp.
- 10. *The Merck Index*, 13th ed., Merck and Co. Inc., Whitehouse Station, New York, 2001, 3963.
- 11. N. A. Rastorgueva, S. Yu. Ryabova, E. A. Lisitsa, L. M. Alekseeva, and V. G. Granik, *Izv. Akad. Nauk, Ser. Khim.*, 2003, 2036 [*Russ. Chem. Bull., Int. Ed.*, 2003, **52**, 2149].
- 12. R. Cumin, E. F. Bandle, E. Gamzu, and W. E. Haefely, *Psychopharmacology (Berl.)*, 1982, **78**, 104.
- S. Yu. Ryabova, N. Z. Tugusheva, L. M. Alekseeva, and V. G. Granik, *Khim.-Farm. Zh.*, 1996, **30**, 7, 42 [*Pharm. Chem. J.*, *Int. Ed.*, 1996, **30**, 7, 472 (Engl. Transl.)].

Received October 13, 2006; in revised form November 13, 2006